COMy 2022 | Treatment approaches for amyloidosis patients with advanced cardiac involvement
Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, discusses treatment approaches for patients with stage III amyloidosis and advanced cardiac involvement. Prof. Merlini first explains the poor survival associated with these patients, and then goes on to discuss novel agents being investigated, including daratumumab. Following this, Prof. Merlini discusses the promise of using monoclonal antibodies that directly target amyloid deposits, such as CAEL-101. To conclude, Prof. Merlini highlights the recent use of murine models and their importance for the development of new drugs in amyloidosis. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Advisory board: Pfizer and Janssen
